Bpifrance

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

MSInsight is a bioinformatics startup specializing in the development of diagnostic and treatment response prediction solutions for microsatellite instability (MSI) cancers. The company offers a platform that utilizes next-generation sequencing data to analyze MSI status, a crucial biomarker in oncology. By providing actionable insights on this biomarker, MSInsight enables healthcare professionals to make informed decisions about patient care, particularly concerning treatment options such as immunotherapy. The focus on diagnostic and prognostic biomarkers of treatment response enhances the ability to improve overall patient outcomes in the oncology market.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

EG 427 is a French biotechnology company that specializes in a novel approach to gene therapy known as pinpoint gene therapy. The company focuses on developing HSV-1-based vectors, leveraging the natural characteristics of Herpes Simplex Virus 1 to create targeted and long-lasting expression of therapeutic genes. This innovative method aims to address spinal cord injury-related disorders, particularly neurogenic bladder conditions, by providing physicians with a potential cure for patients suffering from severe, chronic, and localized diseases. Through its advanced research, EG 427 seeks to transform treatment options for individuals affected by these challenging medical issues.

Ochy is a mobile application that leverages video and artificial intelligence to deliver lab-quality analysis of running techniques, allowing users to assess their performance anytime and anywhere. The app's core technology focuses on analyzing human movement, utilizing algorithms to evaluate biomechanical correctness during running. By identifying an individual's weak points, Ochy generates personalized exercise plans aimed at enhancing performance and preventing injuries. The platform is designed for a diverse user base, including runners without coaches seeking to refine their technique, coaches aiming to better understand and train their athletes, and medical professionals who need to evaluate their patients' movement for rehabilitation purposes. Through its innovative approach, Ochy empowers users to improve their running efficiency and overall athletic performance.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutic solutions. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to overcome treatment resistance and enhance cancer cell survival. Their primary focus is on providing effective treatments for gastrointestinal cancers.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

Primaa is a MedTech company that specializes in the development of an artificial intelligence-based platform for automated and accurate cancer diagnosis. The company’s software utilizes advanced image analysis and deep learning techniques to enhance the detection of major cancer biomarkers, thereby facilitating the identification of tissue damage and supporting personalized treatment plans. By digitizing histological slides and utilizing a comprehensive image database, Primaa's technology allows for a greater number of reliable cancer diagnoses, which improves clinical outcomes in oncology.

Doado is a health technology company that specializes in developing mobile applications for back health management. Its primary product is an e-health application designed to guide users step by step in improving their back health and preventing Musculoskeletal Disorders. The application offers personalized video programs, expert advice from physiotherapists and doctors, and AI-driven progress tracking, enabling individuals and companies to maintain an active lifestyle and reduce the risk of chronic back pain.

Fudzs specializes in sustainable bioeconomy, focusing on developing eco-friendly cell bioproduction processes using advanced bioreactor technology. By integrating biomaterial engineering with cellular science, the company enables cost-effective mass production of cells, opening new market avenues. Fudjs' primary goal is to revolutionize affordable cultivated meat production and transform cell therapies through scalable, future-oriented solutions.

Vaxinano is a biotechnology company founded in 2016, focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Building on 25 years of research and clinical trials led by Pr Didier Betbeder, Vaxinano specializes in creating prophylactic and therapeutic vaccines for infectious diseases. The company employs safe-by-design nanoparticles that adhere to green chemistry principles, facilitating the development of drugs targeting active biomolecules, proteins, and antigens. This innovative approach enables medical researchers to create new vaccines aimed at addressing untreated viral, bacterial, and parasitic diseases.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Hepta Medical is a medical technology company focused on developing innovative treatments for early lung cancer through minimally invasive, nonsurgical methods. The company's flagship product is a microwave ablation platform that employs a specialized catheter equipped with an integrated temperature sensor. This technology allows healthcare professionals to monitor and control the ablation volume in real-time, enhancing the precision of the treatment. By enabling targeted ablation while managing the size of the lesion, Hepta Medical aims to improve patient outcomes and increase the safety and efficiency of cancer therapies.

Enalees is a biotechnology company focused on developing molecular diagnostic tests specifically for pets, with a particular emphasis on leisure animals such as horses. The company has created a platform that provides DNA tests designed to detect the microbes responsible for infectious diseases. These tests enable veterinarians to quickly identify the pathogens causing an animal's illness, facilitating timely and accurate diagnosis. By supplying veterinary clinics with diagnostic test kits, Enalees aims to enhance the efficiency of infectious disease management in animals, ultimately improving animal health outcomes.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

Ray Studios is a Tattoo removal studio that employs hydraulic acoustic wave technology in its "Le Ray Spark" Tattoo removal treatment device.

StarkAge Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients through innovative treatments. The company specializes in developing a platform that utilizes immunotherapy combined with cancer therapy to target and deplete senescent cells associated with age-related diseases. Its research and development efforts are aimed at addressing conditions such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunctions, including hepatic fibroses. By leveraging its unique approach, StarkAge Therapeutics seeks to provide effective therapeutic options for managing these challenging health issues.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Hephaistos Pharma is a biotechnology firm dedicated to advancing oncology treatments through innovative immunotherapy solutions. The company focuses on developing next-generation therapies that utilize active and non-specific immuno-stimulants, which enhance the efficacy of existing antibodies and transform cold tumors into hot targets for the immune system. By addressing unmet medical needs, Hephaistos Pharma aims to provide effective treatment options for patients with incurable cancers. Their platform is designed to stimulate immune responses, thereby improving the overall efficiency of immunotherapy. The firm also offers an online inquiry form on its website for further engagement.

Klineo is a healthcare platform focused on enhancing access to clinical trials for oncology patients. It features an intuitive and intelligent search interface that caters to both healthcare professionals and patients. The platform allows users to efficiently locate relevant clinical trials for specific conditions such as breast, skin, and lymphoma cancers, facilitating contact with trial centers and improving the overall trial search experience. By connecting patients and doctors with appropriate clinical research opportunities, Klineo aims to streamline the process of finding critical treatment options in the oncology field.

Pixacare is a developer of a medical imaging application that enhances wound care management for healthcare professionals. This secure platform automates medical photo management and centralizes critical data for monitoring wounds, making it user-friendly and accessible on both mobile and desktop devices. Designed as a Class I CE-marked digital medical device, Pixacare's application transforms any smartphone camera into a secure documentation tool, enabling home-care staff, surgeons, and dermatologists to effectively monitor and anticipate complications in chronic and post-surgery wounds. By integrating seamlessly with healthcare infrastructures, including Patient Administration Systems and Electronic Health Records, Pixacare ensures data security through hosting on a certified Health Data Hosting server, thereby optimizing the workflow of medical professionals.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. By utilizing a non-ionizing three-dimensional (3D) imaging approach, HawkCell employs specialized MRI sensors designed to accommodate various animal morphologies. The company enhances its services with artificial intelligence algorithms, transforming traditional human MRI technology into dedicated imaging resources tailored for animal diagnostics and scientific exploration. This innovative approach provides veterinary clinics and research labs with precise and insightful tools for improving animal healthcare and advancing research initiatives.

Bioptimus is a biotechnology company focused on developing a universal artificial intelligence foundation model that integrates various scales of biology, from molecules to cells, tissues, and entire organisms. The company's innovative technology leverages generative AI to transform complex multiscale biological data into actionable insights, facilitating significant advancements in scientific research and biomedical innovation. By enabling clients to effectively harness this data, Bioptimus aims to drive breakthrough discoveries and enhance the efficiency of biotechnological processes.

Pixee Medical is a medical technology company based in Chavanod, France, founded in 2017. The company specializes in manufacturing computer-assisted surgery solutions that utilize advanced computer vision and artificial intelligence technologies. Pixee Medical produces innovative surgical navigation tools designed to control the positioning of implants with millimeter precision in three-dimensional space. Its proprietary camera technology, which can be integrated into smartphones or glasses, aids healthcare professionals in performing orthopedic surgeries effectively and affordably, addressing the challenges within the healthcare system.

AQEMIA is a pharmaceutical technology company specializing in drug discovery. It employs a proprietary platform that integrates quantum-inspired physics with machine learning algorithms to accelerate and enhance the identification of new drug candidates tailored to specific therapeutic targets. This innovative approach enables AQEMIA to generate a robust pipeline of novel drug leads, aiming to improve efficiency and accuracy in predicting the affinity between drug candidates and their intended targets.

I.Ceram SA is a France-based company that specializes in the design, manufacture, and marketing of alumina bio-ceramic implants for various joints of the human body. Founded in 2005 and headquartered in Limoges, I.Ceram offers a range of implants for the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot, as well as osteosynthesis products. The company operates both domestically and internationally, emphasizing innovation and high-quality materials in its product offerings. I.Ceram is a subsidiary of Investissement Développement.

Ochy is a mobile application that leverages video and artificial intelligence to deliver lab-quality analysis of running techniques, allowing users to assess their performance anytime and anywhere. The app's core technology focuses on analyzing human movement, utilizing algorithms to evaluate biomechanical correctness during running. By identifying an individual's weak points, Ochy generates personalized exercise plans aimed at enhancing performance and preventing injuries. The platform is designed for a diverse user base, including runners without coaches seeking to refine their technique, coaches aiming to better understand and train their athletes, and medical professionals who need to evaluate their patients' movement for rehabilitation purposes. Through its innovative approach, Ochy empowers users to improve their running efficiency and overall athletic performance.

Huvy is a company that utilizes artificial intelligence to enhance dermatological treatment pathways and provide essential medical information in real-time. It has developed a skin cancer screening application aimed at identifying cancer risks. This application facilitates dermatological screenings, particularly benefiting populations in areas with limited access to medical services. By offering initial diagnostic orientation, Huvy's technology enables patients to receive timely care if there is a suspicion of skin cancer, thus improving early detection and treatment outcomes.

Eligo Bioscience S.A.S is a biotechnology company founded in 2014 and based in Paris, France, specializing in the development of Eligobiotics, a novel class of antimicrobials. These therapeutics are designed to target specific bacteria based on their genomic information, utilizing a combination of CRISPR/Cas technology and engineered phage capsids. This advanced approach allows Eligo to create precision antibiotics aimed at eradicating resistant pathogens and virulent bacteria within the human microbiome. The applications of Eligobiotics extend beyond pharmaceuticals; they also encompass areas such as cosmetics and biodefense, addressing a variety of bacteria-associated diseases and offering next-generation solutions to combat superbugs.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates engineered viral vector vaccines for cancer treatment. The company's innovative platform leverages a portfolio of modified viral vectors, specifically designed for the efficient expression of long strings of tumor neoantigens. This approach is complemented by a toolkit that facilitates the induction of robust antitumor T-cell responses, effectively enhancing cancer-specific cellular immunity in patients. Through its research and development efforts, Nouscom aims to improve cancer treatment outcomes by harnessing the body's immune system to target and combat cancer cells.

BariaTek is a company specializing in innovative bariatric surgery solutions. It focuses on providing minimally invasive procedures that utilize trans-oral access techniques and implantable devices through endoscopy. By doing so, BariaTek aims to replicate the effects of traditional bariatric surgery while minimizing patient discomfort and recovery time. This approach allows patients to receive effective treatment for obesity and related diseases in a less invasive manner, thereby enhancing the overall patient experience and outcomes.

EverImmune is a biotechnology company dedicated to developing innovative treatments in the field of microbiome oncology to support cancer patients. The company specializes in creating live biotherapeutic products that serve as oral adjuvants to enhance anticancer immunotherapies. By focusing on technologies that safely boost the immune system, EverImmune aims to restore sensitivity to immunotherapies, particularly in patients experiencing primary resistance. The company is committed to conducting well-designed clinical trials to evaluate the efficacy of its flagship product, Oncobax, in improving treatment outcomes for cancer patients.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that aims to create customizable drugs specifically designed to replace antibiotics in animal farming. By utilizing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means of combating incurable and deadly infectious diseases. This innovative approach positions the company as a significant player in the field of alternative therapies, addressing the growing concerns surrounding antibiotic resistance and the need for safer, more sustainable health solutions.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

Microoled, established in 2007, specializes in the production of Active Matrix Organic Light Emitting Diode (AMOLED) displays and optical modules from its headquarters and manufacturing facility in Grenoble, France. The company caters to diverse industries including consumer electronics, medical professionals, and security sectors by offering a broad range of products for applications like video glasses, head-mounted sports devices, camera viewfinders, and professional equipment worldwide. Microoled's focus lies in resolving customer-level issues through innovative solutions that anticipate market needs.

X-Pressure is a medical device to measure cerebrospinal fluid pressure to better diagnose brain diseases.

Gleamer is a company specializing in artificial intelligence-based solutions for radiology, focusing on enhancing diagnostic accuracy for medical imaging. By integrating its AI companions into the existing reading environments of radiologists, Gleamer provides an automated second reading that aids in the detection of bone abnormalities, lesions, and other critical details in X-ray images. This technology not only improves efficiency but also helps ensure that all patients receive accurate diagnoses. Currently, Gleamer's solutions are utilized in over 300 institutions across 13 countries, demonstrating its commitment to advancing radiological practices and supporting medical professionals in prioritizing patient care.

Numa Health is a medical bioinformatics health technology company that focuses on empowering individuals to optimize their health capital and well-being. It has developed a digital health platform that offers tools designed to enhance users' commitment to their health. This platform facilitates the reinterpretation of blood test results, providing insights into bodily functions and overall health. By enabling users to measure, understand, and take actionable steps regarding their health, Numa Health aims to support individuals in their journey towards better health management.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

IA Medical transforms raw data into intelligent patient knowledge. Its algorithms help to understand patient data, from diagnosis to follow-up, to support them with its conversational agents but also to set up a hybrid solution of cognitive and behavioral therapies.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The firm aims to create medicinal chemistry solutions that have the potential to significantly improve the lives of cancer patients and their families. By employing a first-in-class approach, Kairos Discovery targets essential cellular mechanisms that contribute to the survival and aggressiveness of both solid tumors and hematological cancers. This commitment to breakthrough oncology technology positions the company as a key player in the advancement of cancer treatment.

Maddie is a healthcare technology company that offers software solutions designed for physiotherapists and other health professionals. Its platform enables effective practice management through features such as dematerialized diaries, online appointment bookings, and customizable websites. These tools assist healthcare providers in organizing waiting lists, optimizing schedules, and managing incoming requests efficiently. By streamlining administrative tasks, Maddie aims to enhance the operational capabilities of health professionals, allowing them to focus more on patient care.

Santé Académie is an innovative online training platform dedicated to enhancing the skills of healthcare professionals. Recognizing the evolving roles of caregivers and the rapid pace of medical knowledge advancement, the company offers high-quality educational videos accessible via web or mobile. Each course is structured into brief episodes lasting 5 to 15 minutes, catering to the busy schedules of doctors, nurses, pharmacists, and care assistants. The curriculum covers essential clinical and regulatory subjects relevant to daily practice, ensuring that participants receive up-to-date information. The courses are certified by the ANDPC and produced by leading experts from esteemed institutions. With a focus on continuous education and engagement, Santé Académie aims to improve patient care throughout the healthcare continuum, a mission supported by over 20,000 professionals and health institutions, including notable organizations such as GHU Paris psychiatrie & neurosciences and Service de Santé des Armées.

Deemea is a developer of a digital medical assistance platform that focuses on enhancing clinical research and the analysis of real-world data. The company utilizes artificial intelligence to streamline various processes, including identifying appropriate databases, expediting contractual and regulatory tasks, and simplifying external model validation. Deemea's platform aims to optimize responses to both internal and external inquiries while valorizing real-world data and clinical studies. By integrating these capabilities, Deemea helps clients accelerate the development and deployment of innovative projects, ensuring efficiency and reliability in the management of imaging data within the clinical research landscape.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.

AlgoTherapeutix is a biotechnology company focused on developing innovative topical treatments for patients suffering from difficult-to-treat conditions, particularly complex pain syndromes. The company targets damaged nerve fibers in the skin to provide localized pain relief while minimizing the systemic side effects often associated with oral medications. AlgoTherapeutix is actively advancing its lead product, ATX01, which has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition that lacks proven therapeutic options. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain and inflammation. By tailoring therapies to the specific needs of patients, AlgoTherapeutix aims to improve treatment outcomes for individuals facing these challenging health issues.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

Previa Medical is a health technology company that focuses on predictive medical solutions. The company operates a platform that analyzes real-time data from patients' electronic health records, including laboratory results, vital signs, and medical history. By leveraging FHIR technology, Previa Medical enables healthcare professionals to identify patients at risk of complications, allowing for timely intervention and treatment. This proactive approach aims to enhance patient outcomes and increase survival rates by ensuring that healthcare providers have access to critical information when making clinical decisions.

Previa Medical is a health technology company that focuses on predictive medical solutions. The company operates a platform that analyzes real-time data from patients' electronic health records, including laboratory results, vital signs, and medical history. By leveraging FHIR technology, Previa Medical enables healthcare professionals to identify patients at risk of complications, allowing for timely intervention and treatment. This proactive approach aims to enhance patient outcomes and increase survival rates by ensuring that healthcare providers have access to critical information when making clinical decisions.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutic solutions. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to overcome treatment resistance and enhance cancer cell survival. Their primary focus is on providing effective treatments for gastrointestinal cancers.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Remedee Labs SAS is a French company founded in 2016, dedicated to developing innovative solutions for chronic pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a personal endorphin stimulator that facilitates on-demand stimulation of the body’s natural endorphins to alleviate pain. Drawing on a decade of pre-clinical and clinical research, Remedee Labs aims to improve the quality of life for the 1.5 billion people worldwide suffering from chronic pain, particularly focusing on conditions such as fibromyalgia. By collaborating with medical practitioners, the company offers a patient-centered digital service platform that enhances the accessibility and effectiveness of endorphin-stimulation therapy for personal healthcare. As it continues to evolve, Remedee Labs plans to expand its platform to address additional chronic pain conditions, positioning itself as a leader in neuromodulation technology for pain management.

Jalon Therapeutics is a biotechnology company focused on developing innovative therapies that inhibit critical yet untargeted tumor signaling pathways. By exploring non-oncogene addiction, the company aims to identify new therapeutic targets and create effective anticancer treatment strategies. Through its research and development efforts, Jalon Therapeutics is dedicated to transforming the lives of cancer patients by providing novel medications that address unmet medical needs in oncology.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is notable for its lead drug, Glunozumab, a monoclonal antibody that employs a novel mechanism of action. This drug hyperactivates both vascular and neuronal NMDA receptors, leading to off-target toxicity that can disrupt the blood-brain and blood-spinal cord barriers, resulting in neuronal excitotoxicity associated with conditions such as stroke and multiple sclerosis. Lys Therapeutics aims to address neuroinflammation and its effects on neurodegeneration through innovative biotherapies.

MOTEN Technologies specializes in developing advanced muscle sensor technology and analysis platforms aimed at preventing musculoskeletal disorders (MSDs). The company offers solutions that measure muscular effort and monitor body motion, providing valuable insights into muscular fatigue. By assisting decision-makers in optimizing workstations and tasks assigned to operators, MOTEN Technologies helps organizations reduce the risks associated with MSDs and enhance employee health and safety. Additionally, the company provides data processing and analysis software services, along with personalized support to ensure effective implementation of its technologies.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at addressing auto-immune and inflammatory disorders. The company's primary product is a peptide designed to maintain a cluster of truncated CD31 molecules at the membrane, which helps moderate overactive immune responses without complete blockade. By facilitating improved treatment options for medical companies, Tridek-One seeks to enhance the quality of life for patients suffering from these conditions.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Apmonia Therapeutics is a biotechnology company focused on developing next-generation peptide-based therapies aimed at targeting the tumor microenvironment to enhance cancer treatment. The company is dedicated to creating innovative drugs for various types of cancer, including glioblastoma, ovarian, colorectal, and pancreatic cancers. By offering new therapeutic perspectives, Apmonia aims to improve the lives of cancer patients and support researchers in developing personalized immunotherapy approaches. Their proprietary therapeutic peptides are designed to provide effective strategies for treating solid tumors, thereby contributing to advanced cancer care.

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

Thabor Therapeutics is a biotechnology company focused on developing innovative treatments for mucosal inflammatory diseases. The company targets a new class of proteins involved in inflammation resolution, aiming to inhibit specific processes in the early stages of inflammation and the recruitment of innate immune cells. By leveraging monoclonal antibodies, Thabor Therapeutics seeks to provide effective solutions for healthcare providers to treat patients suffering from these conditions.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that aims to create customizable drugs specifically designed to replace antibiotics in animal farming. By utilizing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means of combating incurable and deadly infectious diseases. This innovative approach positions the company as a significant player in the field of alternative therapies, addressing the growing concerns surrounding antibiotic resistance and the need for safer, more sustainable health solutions.

Ludocare is a company focused on developing therapeutic robots aimed at assisting patients with chronic diseases and their families. Its innovative devices are designed to complement traditional drug treatments by providing personalized support that empowers patients, particularly children, to enhance their treatment compliance and overall quality of life. By improving patients' abilities and autonomy, Ludocare's solutions seek to foster better disease management and stabilization of essential treatments, ultimately aiming to improve the efficiency of healthcare delivery for those affected by chronic conditions.

Nurea is a company that focuses on providing decision-making support solutions for healthcare professionals, particularly vascular surgeons. It specializes in the development of medical imaging software aimed at the diagnosis of vascular diseases. Nurea's platform automates the analysis of medical images, offering accurate quantitative assessments and decision indicators that assist in managing patient groups during both pre and post-operative monitoring. By streamlining the workflow associated with full-body scan analysis, Nurea enables surgeons to simplify their decision-making processes and improve patient outcomes in the context of cardiovascular diseases.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Osivax is a biotechnology company focused on the development of immunotherapy vaccines aimed at treating infectious diseases. The company's innovative vaccines enhance the uptake into dendritic cells, increasing the immunogenicity of natural proteins to elicit a stronger immune response. This includes a notable activation of CD8 T cells, which is crucial for effective treatment. Osivax's technology offers a universal vaccine approach that targets existing and emerging coronavirus infections, among other globally significant infectious diseases. In addition to infectious diseases, the company's advancements also hold potential for aiding in cancer treatment, providing medical practitioners with new tools to improve patient outcomes.

Intradys is a developer of advanced medical software technologies focused on interventional neuroradiology. The company specializes in creating algorithms that integrate machine learning and mixed reality, providing practitioners with tailored strategies based on various factors, including patient age, medical history, and the suitability of devices for specific pathological conditions. By utilizing images captured before or during procedures, Intradys empowers neuroradiologists to make informed decisions in real-time within the operating room, thereby enhancing the effectiveness and accuracy of surgical interventions.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, focused on developing innovative treatments for food allergies through epicutaneous immunotherapy. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for the treatment of peanut allergies in children, adolescents, and adults. Additionally, DBV Technologies is advancing Viaskin Milk, which is in Phase I/II trials for cow’s milk protein allergy and related conditions, and Viaskin Egg, currently in pre-clinical development for hen’s egg allergy. The company is also exploring a booster vaccine for Bordetella pertussis and has ongoing research programs targeting respiratory syncytial virus, Crohn’s disease, celiac disease, and type I diabetes. Notably, DBV Technologies collaborates with Nestlé Health Science to develop MAG1C, an atopy patch test aimed at diagnosing non-IgE mediated cow’s milk protein allergy in infants and toddlers. Founded by pediatricians and entrepreneurs in 2002, DBV Technologies aims to revolutionize the field of immunotherapy by safely activating the immune system through its proprietary Viaskin technology.

Diabeloop is a medical device company based in Grenoble, France, specializing in innovative solutions for diabetes management. Founded in 2015, the company focuses on developing a closed-loop system that automates insulin delivery for individuals with type 1 diabetes. Its AI-based blood sugar monitoring device integrates a sensor that continuously measures glucose levels, a pump that administers insulin, and a smartphone application that connects these components through an embedded algorithm. This technology aims to enhance the treatment experience by reducing the mental burden on patients, allowing them to manage their condition more effortlessly and live their lives with greater freedom.

Implicity is a developer of a remote monitoring platform that focuses on patients with connected cardiac implants, such as pacemakers and defibrillators. The company's software-as-a-service (SaaS) platform utilizes artificial intelligence to sort and summarize patient data, assessing the criticality of alerts based on the medical context of each individual. This technology allows cardiologists and healthcare professionals to automate the monitoring process, facilitating efficient oversight of patient health and enhancing the quality of care. By consolidating patient information and alerts on a single platform, Implicity aims to improve the management of cardiac conditions and support hospital teams in delivering optimal patient outcomes.

Mobee Travel is a dedicated holiday booking platform designed specifically for individuals with reduced mobility. It offers a selection of over 30,000 accessible accommodations worldwide, each carefully verified to meet the unique needs of travelers with disabilities. The company also provides essential medical equipment on-site, ensuring that customers have everything they require for a comfortable trip. By focusing on streamlined services and reliable options, Mobee Travel aims to simplify the planning and booking process for vacations, catering to the desires and preferences of its clients.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that aims to create customizable drugs specifically designed to replace antibiotics in animal farming. By utilizing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means of combating incurable and deadly infectious diseases. This innovative approach positions the company as a significant player in the field of alternative therapies, addressing the growing concerns surrounding antibiotic resistance and the need for safer, more sustainable health solutions.

Priothera Ltd is a clinical-stage biotechnology company based in Dublin, Ireland, with an additional location in Saint Louis, France. Founded in 2020, Priothera specializes in the development of orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's leading candidate, mocravimod, is designed to reduce the egress of T cell subsets from lymphatic tissue, thereby enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. By providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects, Priothera aims to significantly improve outcomes for patients undergoing such transplants.

Vaxxel is a biotechnology company focused on developing innovative live-attenuated vaccine candidates aimed at preventing critical respiratory diseases, particularly bronchiolitis and pneumonia caused by viral infections. The company specializes in creating novel vaccines targeting human metapneumovirus and other respiratory viruses. By leveraging its proprietary platform, Vaxxel aims to enhance the healthcare industry's ability to combat these significant health threats, ultimately improving patient outcomes and addressing unmet medical needs in the field of respiratory diseases.

Doctolib is an online healthcare booking platform and management software provider based in Paris, France, founded in 2013. The company offers a comprehensive service for healthcare practitioners, enabling them to manage appointments, reduce no-shows, and attract new patients. For patients, Doctolib provides a free and user-friendly online service that allows individuals to easily find local health practitioners and book appointments for medical or dental consultations at any time. By streamlining the appointment process, Doctolib enhances access to healthcare services for both professionals and patients, facilitating better management of consultations and patient interactions.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Susu is a health tech company focused on making healthcare accessible and affordable for individuals within the African diaspora. It offers a comprehensive range of health services, including preventive care, medical treatments, chronic disease management, and the provision of authentic medications. The company operates a platform that delivers health bundle services, ensuring planned, long-term health support for patients. This approach facilitates optimal monitoring of various health conditions, such as pregnancy and chronic diseases, enabling users to access quality healthcare services and insurance. Through its innovative offerings, Susu aims to enhance healthcare access for families across the African diaspora.

Susu is a health tech company focused on making healthcare accessible and affordable for individuals within the African diaspora. It offers a comprehensive range of health services, including preventive care, medical treatments, chronic disease management, and the provision of authentic medications. The company operates a platform that delivers health bundle services, ensuring planned, long-term health support for patients. This approach facilitates optimal monitoring of various health conditions, such as pregnancy and chronic diseases, enabling users to access quality healthcare services and insurance. Through its innovative offerings, Susu aims to enhance healthcare access for families across the African diaspora.

Cell-Easy SAS is a contract development and manufacturing organization (CDMO) based in Toulouse, France, specializing in stem cell services. Established in 2017, the company focuses on providing ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical development projects. By utilizing biological material from healthy donors, Cell-Easy aims to offer a scalable solution that can potentially benefit thousands of patients. The company's innovative production process helps reduce manufacturing costs associated with stem cell therapies, addressing the affordability challenges faced by the healthcare industry in advancing cell therapies.

NaoX Technologies is a company focused on the prevention of neurological disorders through innovative technology. It develops wireless headphones equipped with integrated sensors that passively monitor brain vibrations to record electroencephalogram data in real time. This data is then aggregated and presented on a software dashboard for healthcare providers, facilitating better diagnosis and treatment for patients. The company's mission is to democratize access to neurological disorder prevention, aiming to enhance patient outcomes and support recovery from mental illness.

Cureety is a telemedicine startup focused on enhancing the follow-up and care of cancer patients through its innovative healthcare telemonitoring platform. The company provides tools that assist healthcare professionals in adjusting treatments for cancer patients while also gathering real-world data. This approach not only improves patient management but also supports researchers and industry stakeholders in advancing research initiatives. By transforming the care pathway for cancer patients, Cureety aims to facilitate better health outcomes and foster ongoing improvements in cancer treatment methodologies.

StarkAge Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients through innovative treatments. The company specializes in developing a platform that utilizes immunotherapy combined with cancer therapy to target and deplete senescent cells associated with age-related diseases. Its research and development efforts are aimed at addressing conditions such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunctions, including hepatic fibroses. By leveraging its unique approach, StarkAge Therapeutics seeks to provide effective therapeutic options for managing these challenging health issues.

AlgoTherapeutix is a biotechnology company focused on developing innovative topical treatments for patients suffering from difficult-to-treat conditions, particularly complex pain syndromes. The company targets damaged nerve fibers in the skin to provide localized pain relief while minimizing the systemic side effects often associated with oral medications. AlgoTherapeutix is actively advancing its lead product, ATX01, which has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition that lacks proven therapeutic options. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain and inflammation. By tailoring therapies to the specific needs of patients, AlgoTherapeutix aims to improve treatment outcomes for individuals facing these challenging health issues.

Diaccurate is a biotechnology company based in Paris, France, founded in 2012. The company focuses on researching and developing innovative treatments for various medical conditions, including HIV infection, endocrine-resistant metastatic breast tumors, glioblastoma, and refractory acute myeloid leukemia. Diaccurate is dedicated to exploring new frontiers in oncology to create novel therapeutic approaches aimed at combating difficult-to-treat cancers and improving patient outcomes.

Fysali breaks the taboo by providing remote, non-invasive bladder monitoring. They offer superior clinical accuracy, an exceptional patient experience, and a lower cost of care. They offer remote and noninvasive bladder monitoring services.

Depixus is a biotechnology company that focuses on advanced genomic analysis through its innovative technology designed for real-time examination of biomolecular interactions. By enabling comprehensive analysis across full genomic regions, the company provides a platform that allows researchers to customize the level of sequencing and epigenetic detail required. This capability facilitates the exploration of new biological pathways, the understanding of disease mechanisms, and the development of precision medicines. Depixus aims to overcome the limitations of current sequencing technologies, which struggle to capture dynamic molecular interactions with single-molecule precision, thus enhancing the ability to unlock valuable insights in genomic research.

Spartha Medical is a medical technology company focused on developing innovative coatings designed to enhance the safety of medical devices and consumer products. The company utilizes eco-friendly and biocompatible coatings made from natural biopolymers, which possess antibacterial, antiviral, and anti-inflammatory properties. Their patented technology allows for precise control over the assembly of two distinct polyelectrolytes, enabling the creation of versatile and multifunctional surface coatings tailored to specific applications. By providing effective solutions that protect users from microbial and inflammatory risks, Spartha Medical aims to improve healthcare outcomes and promote safer use of medical devices across various healthcare settings.